Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature-Reference-Cited by-同舟云学术

Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature

Published:2014-07-02 Issue:6 Volume:94 Page:554-557
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Alig Stefan K.¹,Dreyling Martin¹,Seppi Bettina¹,Aulinger Benedikt²,Witkowski Lukas¹,Rieger Christina T.¹

Affiliation:

1. Department of Medicine III; Medical Centre of the University of Munich; Munich Germany

2. Department of Medicine II; Medical Centre of the University of Munich; Munich Germany

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ejh.12396/fullpdf

Reference15 articles.

1. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas;Younes;N Engl J Med,2010

2. Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin;Chen;Onco Targets Ther,2013

3. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease;Durkop;Cell,1992

4. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy;Falini;Blood,1995

5. Extremely rapid and intense induction of apoptosis in human eosinophils by anti-CD30 antibody treatment in vitro;Matsumoto;J Immunol,2004

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Severe insulin resistance in a patient with diabetes after treatment with brentuximab vedotin;BMJ Case Reports;2024-04

2. Severe Cytokine Release Syndrome and Hemophagocytic Lymphohistiocytosis (HLH)-Like Syndrome Following Administration of Combined Brentuximab Vedotin and Nivolumab for Recurrent Classical Hodgkin Lymphoma: A Case Report;Journal of Blood Medicine;2024-01

3. CAR-T treatment for cancer: prospects and challenges;Frontiers in Oncology;2023-12-05

4. Severe Insulin Resistance in a Patient Treated With Nivolumab and Brentuximab-Vedotin for Hodgkin Lymphoma;JCEM Case Reports;2023-11

5. Serious adverse events and coping strategies of CAR-T cells in the treatment of malignant tumors;Frontiers in Immunology;2022-12-08